Table 2.

Antitumor activity of erlotinib/pertuzumab combination therapy and reduction of serum tumor marker concentrations

XenograftResponse (TCR)95% CITGI (%)Tumor freeTumor markerTMI (%)
Calu-30.120.00-0.3171004/12Cyfra 21.197
QG560.390.21-0.59890/12Cyfra 21.180
KPL-40.380.20-0.59853/15sHER292